{"id":11679,"date":"2026-05-27T17:00:00","date_gmt":"2026-05-27T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=23f58350aa2475a76aafbd7224af5e5d"},"modified":"2026-05-27T17:00:00","modified_gmt":"2026-05-27T15:00:00","slug":"immunome-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11679","title":{"rendered":"Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference"},"content":{"rendered":"<p>BOTHELL, Wash.--(BUSINESS WIRE)--<b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54542502&amp;newsitemid=20260527728826&amp;lan=en-US&amp;anchor=Immunome&amp;index=1&amp;md5=6c04a5b4952e08839b53d84589f183a1\" rel=\"nofollow\" shape=\"rect\">Immunome<\/a>,<\/b> Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome\u2019s management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527728826\/en\/2815822\/5\/Immunome_Logo_TM_RGB.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527728826\/en\/2815822\/22\/Immunome_Logo_TM_RGB.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527728826\/en\/2815822\/5\/Immunome_Logo_TM_RGB.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527728826\/en\/2815822\/21\/Immunome_Logo_TM_RGB.jpg\" \/><\/a><p>\nInterested parties can access the live audio webcast for this conference from the Investor Relations section of the company\u2019s website at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.immunome.com&amp;esheet=54542502&amp;newsitemid=20260527728826&amp;lan=en-US&amp;anchor=www.immunome.com&amp;index=2&amp;md5=f61a376aa8a9c1fb8f2ec66296bd6c01\" rel=\"nofollow\" shape=\"rect\"><b>www.immunome.com<\/b><\/a>. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.<\/p><p>\n<b>About Immunome, Inc.<\/b><\/p><p>\nImmunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been submitted to the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-3050, an IND-cleared FAP-targeted radiotherapy; and IM-1617, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nInvestor Contact:\n<br\/>Max Rosett\n<br\/>Chief Financial Officer\n<br\/><a  href=\"mailto:investors@immunome.com\" rel=\"nofollow\" shape=\"rect\"><b>investors@immunome.com<\/b><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>BOTHELL, Wash.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome\u2019s management will present at the Goldman &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11679","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11679"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11679\/revisions"}],"predecessor-version":[{"id":11680,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11679\/revisions\/11680"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}